1Zakrzewska I,Poznanski J.Serum levels of interleukin-10 in patients with ovarian carcinoma in response to chemotherapy [J].Przegl Lek,2003,60(1):18-20.
2Loercher AE,Nash MA,Kavanagh JJ,et al.Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells[J].J Immunol,1999,163(11):6251-6260.
3Ioannide CG,Whiteside TL.T cell recognition of human tumors:implications for molecular immunotherapy of cancer [J].Clin Immunol Immunopath,1993,66(2):91-106.
4Ito N,Nakamura H,Tanaka Y,et al.Lung carcinoma:analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cellsby intracellular cytokine detection with flow cytometry [J].Cancer,1999,85(11):2359-2367.
6Yue FY,Dummer R,Geertsen R,et al.Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-Ⅰ,HLA class-Ⅱ and ICAM-1 molecules [J].Int J Cancer,1997,71(4):630-637.
7Gotlieb WH,Abrams JS,Watson JM,et al.Presence of IL-10 in the ascites of patients with ovarian and other intra-abdominal cancers [J].Cytokine,1992,4(5):385-390.
9Zeimet AG,Widschwendter M,Knabbe C,et al.Ascitic Interleukin-12 is an independent prognostic factor in ovarian cancer [J].J Clin Oncol,1998,16(5):1861-1868.
10Huang S,Xie K,Bucana CD,et al.Interleukin-10 suppresses tumor growth and metastasis of human melanoma cells:potential of angiogenesis [J].Clin Cancer Res,1996,2(12):1969-1979.
